JAK Inhibitors in Patients With Cytopenic Myelofibrosis
A brief discussion on the role that JAK inhibitors play in cytopenic myelofibrosis and how best to optimize care with sequencing and dose adjustment.
Transcript:
John O. Mascarenhas, MD: Let’s get back to our case. So this is the gentleman who’s symptomatic, big spleen, almost 150,000 hemoglobin, is close to 14, sees Kristen in Ann Arbor, and she starts him on 10 mg twice a day of ruxolitinib…. After 6 months, [she] ends up dose reducing to 5 mg twice daily, mainly because the cytopenia has become quite limiting, and we’ve all seen these kinds of cases where that can happen. The problem is, now he’s coming back and complaining about worsening fatigue [and] night sweats. His spleen is clearly bothering him, and today in the visit with Kristen, his platelet count is 46,000, the hemoglobin went from 14 to 12, he is feeling unwell, and he’s telling Kristen, “I just feel so fatigued. Maybe I need a transfusion.” What are you going to do with a patient like this? You’ve dosed reduced them, they’re feeling symptomatic, [and] their counts are now lower.
Kristen M. Pettit, MD: My first question, and it’s a very difficult question to answer, is whether the cytopenias and some of what he’s feeling [are] related to disease progression toxicities from the medication. I think that can be hard to parse out often. In his case, though, it sounds like his night sweats, abdominal pain—I assume that means his spleen is larger. It sounds to me like the disease is not well controlled with ruxolitinib and it’s not just a matter of drug-related hematologic toxicities. That’s obviously a worrisome sign. The other very worrisome sign is…that we’ve had to de-escalate the ruxolitinib dose because of this cytopenia down to 5 mg [twice daily]; that’s definitely a red flag in my mind. As we’ve mentioned a couple of times, I think dose intensity matters in myelofibrosis, and maximizing the dose of JAK inhibition that you can get into patients does matter. So lots of red flags here for possible disease progression or at least lack of disease control on his current JAK inhibitor. I think I would want to reassess the disease status, probably, as I mentioned before, do next-generation sequencing to see if there’s anything biologically that has changed or progressed since his disease phenotype has changed from a more proliferative to a more cytopenic disease. In the past, we may have considered trying to push through with ruxolitinib or something like that in a patient in this situation. But now we have another option for these patients with cytopenic MF [myelofibrosis], which is pacritinib, the newer JAK inhibitor that was approved in February 2022. At this point, I think there is plenty reason to switch agents, and pacritinib would be my go-to for all the benefits that Andrew just mentioned about pacritinib in cytopenic MF. The benefit of trying to maximize the JAK2 inhibition while minimizing the hematologic toxicities and trying to inhibit other pathways that might be now driving his disease, such as IRAK1 and maybe ACVR1. Although it doesn’t sound like he’s too anemic with that hemoglobin of 12, but it has been a reduction for him. That might be an added benefit, as well, if we could get that anemia a bit better tuned up. Then I think also, as we’ve been talking about, if he is a transplant candidate…circling back to that idea at this time would be appropriate too.
Transcript edited for clarity.
Improving Disease Modification and Immune Responses in Myelofibrosis With Pelabresib
November 16th 2024David M. Swoboda, MD, and Andrew Kuykendall, MD, spoke about the current treatment strategies and potential advancements that may improve outcomes such as spleen volume reduction in the myelofibrosis field.
